Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients

Pharmacological Reports

Volumn 64, Issue 1, 2012, Pages 212-216

  Kotani, Kazuhiko ^a,b   Yamada, Toshiyuki ^a   Miyamoto, Michiaki ^a   Ishibashi, Shun ^a   Taniguchi, Nobuyuki ^a   Gugliucci, Alejandro ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Oxidative stress; SAA; SAA LDL

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM AMYLOID A; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; SEX DIFFERENCE; TREATMENT DURATION;

EID: 84862184115     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(12)70748-x     Document Type: Article

References (18)

1. Arca M, Gaspardone A: Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs, 2007, 67, Suppl 1, S29-42.
2. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP: Atorvastatin: safety and tolerability. Expert Opin Drug Saf, 2010, 9, 667-674.
3. Aviram M, Rosenblat M, Bisgaier CL, Newton RS: Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis, 1998, 138, 271-280. (Pubitemid 28314098)
4. de Ferranti SD, Rifai N: C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol, 2007, 16, 14-21. (Pubitemid 46049026)
5. Jasińska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep, 2007, 59, 483-499.
6. Kotani K, Satoh N, Yamada T, Gugliucci A: The potential of serum amyloid A-LDL as a novel biomarker for cardiovascular disease risk. Clin Lipidol, 2010, 5, 489-495.
7. Kuklińska AM, Mroczko B, Musiał WJ, Sawicki R, Kozieradzka A, Usowicz-Szaryńska M, Kamiński K et al.: Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress. Pharmacol Rep, 2010; 62, 883-890.
8. Marzilli M: Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs, 2010, 10, Suppl 1, S3-9.
9. O'Brien KD, Chait A: Serum amyloid A: the "other" inflammatory protein. Curr Atheroscler Rep, 2006, 8, 62-68. (Pubitemid 43675756)
10. Riesen WF, Engler H, Risch M, Korte W, Noseda G: Short-term effects of atorvastatin on C-reactive protein. Eur Heart J, 2002, 23, 794-799. (Pubitemid 35238493)
11. Sasaki S, Kuwahara N, Kunitomo K, Harada S, Yamada T, Azuma A, Takeda K, Nakagawa M: Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol, 2002, 89, 386-389. (Pubitemid 34142510)
12. Schaefer EJ, McNamara JR, Asztalos BF, Tayler T, Daly JA, Gleason JL, Seman LJ et al: Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol, 2005, 95, 1025-1032. (Pubitemid 40544302)
13. Steinberg D, Witztum JL: Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol, 2010, 30, 2311-2316.
14. Tamura A, Watanabe T, Nasu M: Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circ J, 2003, 67, 816-820. (Pubitemid 37229216)
15. van Tits LJ, van Himbergen TM, Lemmers HL, de Graaf J, Stalenhoef AF: Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2006,185, 307-312.
16. Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K, Bäumer AT, Linz W et al: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol, 2002, 22, 300-305. (Pubitemid 34127043)
17. Wiklund O, Mattsson-Hultén L, Hurt-Camejo E, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med, 2002, 251, 338-347. (Pubitemid 34592108)
18. Zhu Q, McMaster J, Mymin D, Dembinski T, Hatch G, Choy PC, Kroeger EA: Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients. Mol Cell Biochem, 2000, 207, 9-17. (Pubitemid 30399365)